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Aims: The kidneys of patients with diabetes mellitus usually exhibit a characteristic pattern
of linear immunofluorescent staining for immunoglobulin G (IgG) along the glomerular and
tubular basement membranes. However, the association between linear IgG staining and
the renal prognosis remains unclear.
Methods: Among 223 patients with diabetes who underwent renal biopsy from 1985 to 2010
and were confirmed to have pure diabetic nephropathy according to the classification of
Tervaert et al., 165 patients (glomerular classes I to III) were enrolled in this study.
Immunofluorescent staining was classified into three categories according to its intensity
(0 = none, 1 = weakly positive, and 2 = positive). Cox proportional hazards regression analy-
sis was used to calculate the hazard ratio (HR) and 95% confidence interval (CI) for death-
censored renal death, with each regression analysis employing four levels of multivariate
adjustment.
Results: After adjustment for important clinical factors at the time of renal biopsy, the HR for
death-censored renal death in patients with an IgG staining score of 1 or 2 was, respectively,
3.01 (95% CI: 1.05–8.68) and 4.68 (1.67–13.1) compared with patients who had a staining score
of 0. Even after adjustment for clinical variables and pathological findings, the HR for IgG
score of 1 or 2 was higher than that for an IgG score of 0, and it was, respectively, 2.22 (0.71–
7.00) and 3.76 (1.27–11.2).
Conclusions: More intense linear IgG staining is associated with a higher HR for renal death,
which suggests that linear immunofluorescent staining for IgG may be a prognostic indica-
tor in patients with diabetic nephropathy.
# 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under
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1. Introduction
Diabetic nephropathy (DN) is the most common cause of
chronic kidney disease (CKD), and is clinically characterized
by persistent albuminuria (also referred to as macroalbumi-
nuria or proteinuria), a steady decline of the glomerular
filtration rate (GFR), and elevation of blood pressure [1].
Established DN has three histopathological characteristics,
which are mesangial expansion that progresses to Kimmel-
stiel Wilson lesions (nodular lesions), thickening of the
glomerular basement membrane (GBM), and hyalinosis of
the afferent and efferent arterioles [2]. A recent classification
of DN [3] is useful for categorizing the development of these
diabetic lesions, and we and others have reported on the
relationship between these characteristic pathological find-
ings and the clinical outcome [4–6]. These findings can be
detected by light microscopy (LM), for GBM thickening that is
confirmed by electron microscopy (EM). On the other hand,
immunofluorescence (IF) of the kidneys in diabetic patients
usually reveals a characteristic pattern of linear homoge-
Fig. 1 – Flowchart of study participants.
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lar and tubular basement membranes without detection of
immune complex deposits by EM [2]. Although the mecha-
nisms underlying some of the characteristic microscopic
changes of DN have been revealed [2,7], the cause of
immunofluorescent IgG staining remains unclear. In other
renal diseases such as IgA nephropathy and lupus nephritis,
immunostaining shows immune complex deposits, and an
association between such findings and the clinical outcome
has been reported [8,9]. However, the relationship between
immunostaining findings and the prognosis of DN has not
been investigated before. Accordingly, we studied the
association between linear IgG staining of renal biopsy
specimens and the clinical outcome of DN, especially the
long-term renal prognosis, to assess the implications of IgG
staining.
2. Materials and methods
2.1. Study design
Among 310 patients with diabetes mellitus who underwent
renal biopsy at our hospital from March 1985 to January 2010
and were confirmed to have diabetic nephropathy, 165
patients were considered to be eligible and were enrolled in
this study. Diabetic nephropathy was diagnosed by at least
two renal pathologists and/or nephrologists, and the diagnosis
was re-evaluated according to Tervaert’s classification [3].
Exclusion criteria were kidney transplantation, coexistence of
other renal diseases (except for nephrosclerosis), fewer than 5
glomeruli obtained by renal biopsy, glomerular class IV, and
no glomeruli or global screlosis in the specimen for IgG
immunofluorescence (Fig. 1). The study protocol was reviewed
and approved by the ethics committee of Toranomon Hospital
in July 2013. This study was registered with the University
Hospital Medical Information Network (UMIN) in August
2013. The UMIN identification number of this study is
UMIN000011448.2.2. Laboratory parameters and definitions
HbA1c levels were presented as National Glycohemoglobin
Standardization Program values according to the recommen-
dations of the Japanese Diabetes Society and International
Federation of Clinical Chemistry values [10]. As in our previous
study, hematuria was defined and the average annual values,
such as urinary protein excretion, systolic and diastolic blood
pressure, HbA1c, and hemoglobin were calculated [4].
2.3. Renal biopsy and pathological classification
The indications for renal biopsy were proteinuria of more
than 0.5 g/day and/or atypical DN, such as nephritic syn-
drome with short duration of diabetes and renal involvement
without diabetic retinopathy and/or with hematuria as we
previously reported [4]. All renal biopsy were performed with
the consent of each patient. Tissue was obtained by needle
biopsy and the specimens were processed for LM, IF, and EM.
Specimens for LM were fixed in 6% formalin, embedded in
paraffin, cut into 1–2 mm sections, and stained with hema-
toxylin and eosin, periodic acid Schiff, Weigert’s elastica-van
Gieson, Masson trichrome, and periodic acid methanamine
silver stain. Specimens for IF were snap-frozen in a mixture of
dry ice and acetone, and then were cut into 3–4 mm sections
on a Damon/IEC cryostat at 20 8C. After being fixed in
acetone, the sections were incubated for 30 min in a moist
chamber at 37 8C with fluorescein isothiocyanate (FITC)-
conjugated rabbit antiserum for human IgG, IgA, and IgM, as
well as complement component (C) 1q, C3, and C4 (Behring-
werke, West Germany, and Fuji Zoki, Japan). Then the slides
were examined under an Olympus AX80 fluorescence
microscope (Japan) equipped with optimal excitation and
barrier filters for FITC. For EM, renal biopsy cores were
preserved in 3% phosphate-buffered glutaraldehyde, diced
into 1 mm cubes, rinsed in distilled water, transferred to 1%
aqueous osmium tetraoxide, and embedded in TAAB Emix
resin. Sections were cut at 0.5 mm, mounted on glass slides,
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tetraborate for 15 s on a hot plate at 15 8C. After cooling, light
microscopy was performed to find assessable glomeruli. Then
sections were cut with a diamond knife on a Leica Ultracut E
ultramicrotome, and were coated with gold particles approx-
imately 95 nm in diameter. Subsequently, the sections were
stained by immersion for 7 min in 50% alcohol-saturated
uranyl water and for 3 min in Reynolds lead citrate, followed
by three washes in distilled water. Then the sections were
examined under a Philips 400 transmission electron micro-
scope. We re-evaluated the GBM thickness of the patients
without glomerular collapse or a global sclerosis in the
specimen for EM by using Haas’ direct measurement/
arithmetic mean method [11]. We could re-evaluate the
GBM thickness in 109 patients, and their mean GBM thickness
was 762.0  221.3 nm. Classification of DN and histological
scoring were done according to the criteria of Tervaert et al.
[3], and exudative lesions were also evaluated, as in our
previous study [4]. Linear immunofluorescent staining for IgG
that is characteristic of DN was classified into three categories
according to its intensity (0 = none (equal to background
intensity), 1 = weakly positive, 2 = positive) (Fig. 2). Classifi-
cation of DN was performed by two renal pathologists, while
scoring of linear immunofluorescent IgG staining was done by
a renal pathologist and a nephrologist who were unaware of
the clinical status of each patient. We excluded coexistence of
anti-GBM glomerulonephritis or membranous glomerulone-
phritis which has similar immunofluorescent staining for IgG
by considering clinical course and confirming that there is no
serum anti-GBM antibody and no subepithelial electron
dence deposit or intramembranous deposit in the specimen
for EM. Digital photographs were taken by an Olympus DP72
camera (Olympus, Japan) operating with Olympus DP2-BSW
software. To assess the reproducibility of our IgG scoring
method, a single renal pathologist (Prof. K.O.) scored the IgG
staining by evaluating the digital images without access to
clinical data. There was good agreement between the original
scores and the renal pathologist’s scores (weighted k value
[12]: 0.62). We adopted the original scores for analysis because
we considered that real-time scoring through a microscope
was most reliable for immunofluorescent studies and
because inter-observer agreement was high.Fig. 2 – Examples of linear immunofluorescent staining for IgG 
There is no IgG staining (equal to background). Magnification T4
Score = 2. Clearly positive IgG staining. Magnification T400.2.4. Endpoint
The primary endpoint was renal death, which was defined as
commencement of dialysis due to ESRD. None of the patients
received kidney transplantation during follow-up.
2.5. Statistical analyses
Data were summarized as percentages or as mean values  -
standard deviation [SD]) when appropriate. Categorical vari-
ables were analyzed with the x2 test or Fisher’s exact test, as
appropriate, while continuous variables were compared by
using the t-test, Mann–Whitney U test, Kruskal–Wallis H test,
or ANOVA, as appropriate. Correlations of the IgG score with
histopathological findings were evaluated by Spearman’s
correlation analysis. To assess inter-observer concordance,
weighted k statistics were calculated [12]. k Values were
expressed with the 95% confidence interval (CI) based on the
SE (non-zero) and were interpreted as follows: k < 0.2 means
poor agreement, while 0.21–0.40 is fair, 0.41–0.60 is moderate,
0.61–0.80 is good, and 0.81–1.00 is very good agreement beyond
chance [13]. Cumulative survival was estimated by drawing
Kaplan–Meier survival curves, and survival rates were
compared with the log-rank test. The Cox proportional
hazards model was used to calculate hazard ratios (HRs)
and 95% CIs for death-censored renal death. In Cox model 1,
HRs were adjusted for age, gender, eGFR, type of diabetes,
urinary protein excretion, systolic blood pressure, body mass
index (BMI), and HbA1c at the time of renal biopsy. In model 2,
HRs were adjusted for all of the above covariates plus diabetic
retinopathy and red blood cells in urinary sediment at the time
of renal biopsy. In model 3, HRs were adjusted for the clinical
variables in model 2 and other renal pathological findings,
such as the glomerular class, interstitial fibrosis and tubular
atrophy (IFTA) score, interstitial inflammation score, arteriolar
hyalinosis score, arteriosclerosis score, and presence of
exudative lesions. Finally, in model 4, HRs were adjusted for
the covariates in model 3 and GBM thickness (GBM thickness/
100). We tested for a formal interaction between IgG score and
GBM thickness in this model 4. The IgG score  GBM thickness/
100 interaction term (P = 0.26) was not statistically significant.
A P value of less than 0.05 was considered to indicate aalong the glomerular basement membrane. (A) Score = 0.
00. (B) Score = 1. Weak IgG staining. Magnification T400. (C)
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performed with SPSS software (version 20.0, Chicago, IL).
3. Results
Of the 310 patients screened, 165 met the study entry criteria.
A flowchart showing the disposition of the patients is
displayed in Fig. 1. The mean follow-up period was
75.5  72.7 months.
Of the 165 patients, 117 were men (71%). The mean (SD)
age at the time of renal biopsy was 55.0  13.2 years (range: 21
to 82 years). A total of 144 patients (87%) had type 2 diabetes,
and 109 patients (66%) had diabetic retinopathy. Mean BMI was
24.2  4.1 kg/m2. The mean systolic and diastolic blood
pressures at admission were 144.7  19.9 mmHg and
81.5  12.3 mmHg, respectively. The mean baseline serum
creatinine level was 1.41  0.72 mg/dL (0.4 to 4.2), mean
creatinine clearance was 54.7  28.0 mL/min, and mean eGFR
was 52.3  22.9 mL/min per 1.73 m2 [14]. Urinary protein
excretion was 2.90  3.22 g/day. Twenty patients (12%) had
hematuria (i.e., more than 5 erythrocytes per high-power
field). The mean hemoglobin was 12.4  2.3 g/dL, mean HbA1c
was 8.0  1.9% (63.0  20.8 mmol/mol), and serum albumin
was 3.2  0.7 g/dL. At the time of renal biopsy, 109 patientsTable 1 – Baseline clinical findings in groups stratified accord
All 
(n = 165) 
Male (%) 71 
Age (year) 55.0  13.2 
Body mass index(kg/m2) 24.2  4.1 
Type1 DM (%) 13 
Duration of DM(years) 14.8  7.9 
Systolic blood pressure (mmHg) 144.7  19.9 
Diastolic blood pressure (mmHg) 81.5  12.3 
Diabetic retinopathy (%) 66 
Serum creatinine(mg/dl) 1.4  0.7 
(0.4–4.2) 
Creatinine clearance (ml/min) 54.7  28.0 
eGFR (ml/min/1.73m2) 52.3  22.9 
Urinary protein excretion (g/day) 2.9  3.2 
Serum albumin(g/dl) 3.2  0.7 
HbA1c (%) 8.0  1.9 
(mmol/mol) 63.0  20.8 
Hemoglobin (g/dl) 12.4  2.3 
RBC in urinary sediment (%) 12 
ACE-I or ARB (%) 66 
Number of antihypertensive agent 2.1  1.4 
ESA (%) 6 
OHA therapy (%) 32 
Insulin therapy (%) 49 
Abbreviations: Duration of DM: estimated duration of diabetes mellitus, eG
blood cells > 5/HPF in sediment, ACE-I or ARB: treatment with an angio
blocker, respectively, ESA: erythropoietin-stimulating agent, OHA: oral hy
basal-supported oral therapy).
* P < 0.01: vs. a score of 0.
y P < 0.05: vs. a score of 0.
z P < 0.01: vs. a score of 1.
§ P < 0.05: vs. a score of 1.(66%) were being treated with an angiotensin-converting
enzyme inhibitor (ACE-I) or an angiotensin II type I receptor
blocker (ARB) and the mean number of antihypertensive
agents was 2.1  1.4. A total of 9 patients (6%), 52 patients
(32%), and 80 patients (49%) were being treated with
erythropoietin-stimulating agents, oral hypoglycemic agents,
and insulin including basal-supported oral therapy, respec-
tively (Table 1).
Clinical findings at the time of renal biopsy are compared
among groups based on the immunofluorescent IgG staining
scores in Table 1. There were significantly more patients with
type 1 diabetes in the group with a score of 2 than in the group
with scores of 0 or 1. Coexistence of diabetic retinopathy was
significantly less frequent in patients with a score of 0 than in
those with a score of 1 or 2. The eGFR was significantly lower in
patients with a score of 2 than in those with a score of 0.
Urinary protein excretion was significantly greater in patients
with scores of 1 or 2 than in those with a score of 0. Use of ACE-I
or ARB was significantly more frequent in patients with a score
of 1 than in those with a score of 0, and patients with a score of
1 also used significantly more antihypertensive agents.
Histopathological findings in the groups with each immu-
nofluorescent IgG staining score and the correlations between
the IgG scores and each histopathological finding are shown in
Table 2. The IgG staining score showed a weak correlation withing to the immunofluorescent IgG staining score.
Score 0 Score 1 Score 2
(n = 28) (n = 52) (n = 85)
82 75 66
55.5  11.4 58.7  13.8 52.6  13.1z
24.7  5.7 24.3  3.6 23.9  3.8
4 4 21y,z
12.9  9.3 15.5  8.5 14.8  7.0
138.0  17.9 148.4  19.1y 144.7  20.7
81.5  12.6 82.0  12.6 81.1  12.1
39 69* 73*
1.1  0.4 1.3  0.7 1.5  0.8y,§
(0.4–2.3) (0.5–4.2) (0.5–3.9)
67.9  27.8 53.7  23.5y 51.1  29.5*
61.3  19.4 54.5  22.0 48.1  23.7*
1.3  1.8 3.0  2.9* 3.4  3.6*
3.7  0.6 3.2  0.6* 3.1  0.8*
7.7  1.6 7.6  1.6 8.3  2.1
59.8  17.1 59.1  17.2 66.5  23.4
13.7  2.0 12.6  2.3 11.9  2.3*
11 8 15
46 77* 66
1.5  1.1 2.4  1.6y 2.0  1.4
4 4 7
29 40 27
29 46 57y
FR: estimated glomerular filtration rate, RBC in urinary sediment: red
tensin-converting enzyme inhibitor or angiotensin II type I receptor
poglycemic agent, Insulin therapy: treatment with insulin (including
Table 2 – Histopathological findings in groups with each score for linear immunofluorescent IgG staining and correlations
between the IgG scores and histopathological findings.
All Score 0 Score 1 Score 2 IgG Score (r)
(n = 165) % (n = 28) % (n = 52) % (n = 85) %
Glomerular class I 8 25 8 2 0.35
IIA 27 54 29 17
IIB 33 7 31 43
III 32 14 32 38
IFTA score 0 11 29 10 6 0.27
1 32 42 31 29
2 35 25 38 37
3 22 4 21 28
Inter-infla score 0 15 46 12 7 0.26
1 78 50 78 87
2 7 4 10 6
Hyalinosis score 0 9 29 8 4 0.22
1 10 11 10 9
2 81 60 82 87
A-sclerosis score (n = 155) 0 11 19 10 9 0.07
1 52 58 46 54
2 37 23 44 37
Exudative lesions (+) 52 25 56 59 0.19
GBM thickness (nm) 762.0  221.3 613.7  173.8 720.5  197.5 855.3  214.4*,y 0.41
(n = 109) (n = 22) (n = 36) (n = 51)
Number of glomeruli 17.0  11.2 13.5  9.0 19.3  11.2* 16.7  11.7
Abbreviations: IFTA: interstitial fibrosis and tubular atrophy, Inter-infra: interstitial inflammation, Hyalinosis: arteriolar hyalinosis, A-sclerosis:
arteriosclerosis, GBM: glomerular basement membrane, Number of glomeruli: mean number of glomeruli obtained by renal biopsy,
r: correlation coefficient between the IgG score and each histopathological finding.
* P < 0.05: vs. a score of 1.
y P < 0.05: vs. a score of 1.
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weak correlation with the IFTA score (r = 0.27), interstitial
inflammation score (r = 0.26), arteriolar hyalinosis score
(r = 0.22), and presence of exudative lesions (r = 0.19). Howev-
er, the IgG staining score was not significantly correlated with
the arteriosclerosis score (r = 0.07). GBM thickness was more
strongly correlated with the IgG scores than other pathological
findings (r = 0.41), and there was a significant difference of
GBM thickness between patients who had an IgG score of 2 and
those with scores of 0 or 1.
Clinical findings during the follow-up period and at final
follow-up are displayed in Table 3. Average urinary protein
excretion during follow up was significantly greater in the
patients with scores of 1 or 2 than in those with a score of 0.
The average systolic blood pressure was significantly higher in
patients who had a score of 1 than in those with a score of 0.
There were no significant differences in the use of ACE-I or
ARB during the follow-up period among the patients with
different scores. At final follow-up, the patients with a score of
0 were taking significantly fewer antihypertensive agents than
patients with a score of 1. Significantly fewer patients with
a score of 0 than with a score of 2 were on insulin at final
follow-up.
Renal death occurred in 63 patients during follow-up, and
the number of renal deaths in each glomerular class is listed in
Table 3. A total of 17 patients died during follow-up.
Kaplan–Meier survival curves stratified according to the
immunofluorescent IgG staining scores are shown in Fig. 3.
There was a significant difference of renal survival among the
IgG score groups. The 5-year renal survival rate was estimatedto be 100% for an IgG score of 0, 75.6% for a score of 1, and 47.4%
for a score of 2.
The adjusted HRs of the IgG scores for renal survival are
shown in Fig. 4. In model 1, the HRs for IgG scores of 1 and 2
were significantly higher compared with a score of 0, being
2.86 (95% CI: 1.00–8.16) and 4.55 (95% CI: 1.63–12.7),
respectively. In model 2, the HRs for IgG scores of 1 and 2
were also significantly higher compared with a score of 0,
being 3.01 (95% CI: 1.05–8.68) and 4.68 (95% CI: 1.67–13.1),
respectively. In model 3, the HRs for IgG scores of 1 and 2
were adjusted for clinical variables in model 2 and other
renal pathological findings, and were respectively 2.22 (95%
CI: 0.71–7.00) and 3.76 (95% CI: 1.27–11.2) compared with an
IgG score of 0. Also in model 4, even after adjustment for GBM
thickness and the covariates in model 3, the HRs for IgG
scores of 1 and 2 were higher than that for an IgG score of 0,
being 1.84 (95% CI: 0.41–8.20) and 4.84 (95% CI: 1.13–20.7),
respectively.
4. Discussion
Although the association between characteristic linear immu-
nofluorescent staining for IgG and the renal outcome of DN
has not been assessed before, a few old studies investigated
the relationship between linear IgG staining and clinical
findings at the time of renal biopsy [15,16]. Westberg et al. [15]
examined immunofluorescence findings in 37 samples of
diabetic kidney tissue divided into three pathologic groups. In
the group of normal histology or minimal changes, four
Table 3 – Clinical findings during the follow-up period and at final follow-up in groups stratified according to the
immunofluorescent IgG staining score.
All Score 0 Score 1 Score 2
(n = 165) (n = 28) (n = 52) (n = 85)
Average UP (g/day or g/Cr) 3.3  3.0 1.3  1.3 3.3  2.8* 4.0  3.2*
Average sBP (mmHg) 139.6  15.5 134.6  14.4 141.5  14.1y 140.2  16.5
Average dBP (mmHg) 77.8  8.9 76.9  9.2 78.1  9.2 77.8  8.8
Average HbA1c (%) 7.6  1.4 7.3  1.3 7.4  1.1 7.8  1.6
(mmol/mol) 58.7  15.7 55.9  13.7 56.4  12.3 61.0  17.8
Average Hb (g/dl) 11.9  2.0 13.2  1.7 12.1  1.8* 11.4  2.1*,z
ACE-I or ARB (%) 86 79 94 84
Final number of antihypertensive agent 3.0  1.7 2.5  1.9 3.4  1.9y 2.9  1.4
Final ESA (%) 47 32 46 52
Final OHA therapy (%) 25 29 29 21
Final insulin therapy (%) 61 43 64 65y
Number of renal death 63 5 18 40
Abbreviations: Average UP: average annual urinary protein excretion, Average sBP: average annual systolic blood pressure, Average dBP:
average annual diastolic blood pressure, Average HbA1c: average annual HbA1c, Average Hb: average annual hemoglobin level, ACE-I or ARB:
treatment with an angiotensin-converting enzyme inhibitor or angiotensin II type I receptor blocker, respectively, for more than three months
(n = 137) or half of the follow-up period (n = 129), Final number of antihypertensive agents, Final ESA, Final OHA therapy, Final insulin therapy
are respectively the number of antihypertensive agents, use of erythropoietin-stimulating agents, use of oral hypoglycemic agents, and use of
insulin (including basal-supported oral therapy) at final follow-up or immediately before commencement of dialysis.
* P < 0.01: vs. a score of 0.
y P < 0.05: vs. a score of 0.
z P < 0.01: vs. a score of 1.
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four kidneys were negative for IgG staining. In another group
of moderate glomerular changes, one kidney showed 3+ linear
IgG staining, three kidneys were 2+, two kidneys were 1+, andFig. 3 – Renal survival rates and IgG scores.The 5-year renal su
75.6% for a score of 1, and 47.4% for a score of 2. Median time f
months for IgG scores of 0 and 1 versus 56 months for an IgG s
commencement of dialysis after renal biopsy.four kidneys were negative. These results suggest that the
severity of clinical and pathological findings, especially
glomerular lesions, may be associated with the intensity of
linear immunofluorescent staining for IgG, which is inrvival rate was estimated to be 100% for an IgG score of 0,
or commencement of dialysis after renal biopsy was >144
core of 2. Abbreviation: median time: median time until
Fig. 4 – Univariate and multivariate Cox proportional hazard models incorporating pathological variables at the renal end-
point. Model 1: Adjusted for age, gender, estimated glomerular filtration rate, type of diabetes, urinary protein excretion,
systolic blood pressure, body mass index, and HbA1c at the time of renal biopsy. Model 2: Adjusted for the above plus
diabetic retinopathy and red blood cells in urinary sediment at the time of renal biopsy. Model 3: Adjusted for the clinical
variables in model 2 and other renal pathological findings, such as the glomerular class, interstitial fibrosis and tubular
atrophy score, interstitial inflammation score, arteriolar hyalinosis score, arteriosclerosis score, and presence of exudative
lesions. Model 4: Adjusted for the factors in model 3 and GBM thickness/100. Abbreviations: HR: Hazard ratio, 95% CI: 95%
confidence interval.
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class increased as the IgG staining score increased, and there
was a weak, but significant, correlation between the IgG score
and the glomerular class (r = 0.35). In addition to weak
correlations with glomerular class and other pathologic
findings, the HRs for renal survival (adjusted for all renal
pathological findings) tended to increase as the IgG score
increased. Therefore, linear immunofluorescent staining for
IgG may be an independent pathologic indicator of the renal
prognosis in DN.
The mechanism of linear immunofluorescent staining for
IgG in DN has not been clarified, but some hypotheses have
been suggested [15–17]. One is that structural changes of the
basement membrane lead to entrapment of serum proteins,
possibly due to changes of membrane permeability, resulting
in thickening of the GBM [16,17]. Generally, an increased
excretion of albumin and anionic proteins has been found in
the early stage of DN because of the decrease in the number of
anionic charge sites in the lamina rere externa due to a
decrease of heparin sulphate proteoglycan [18,19]. Renalfractional clearances of the anionic IgG4 and the anionic-
cationic IgG clearance ratio increase in the early DN, whereas
macroalbuminuria is associated with impaired barrier size
selectivity due to an increase in large pore area rather than
charge selectivity impairment [20–22].
Miller et al. [17] reported immunofluorescent staining for
IgG and albumin along the tubular basement membrane and
GBM in patients with severe diabetic nephropathy, while there
was negative or minimal staining in normal kidneys or those
from patients with other renal diseases. In our patients,
urinary protein excretion and GBM thickness increased and
serum albumin level decreased as the IgG score increased.
These results are compatible with the above hypothesis.
Interestingly, in our multivariate model 4, higher IgG scores
showed higher HRs for the renal endpoint even after
adjustment for clinical and pathological parameters including
GBM thickness, although the sample size was small. There-
fore, linear immunofluorescent staining for IgG could be a
useful indicator of renal prognosis independent of other
pathological findings.
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et al. [15] concluded that the consistent presence of albumin
and the frequent absence of complement components at the
sites of staining provided evidence against an immunologic
mechanism for this immunofluorescent staining. The low
frequency (13.1%) of detecting complement at the sites of IgG
staining in our patients was compatible with this explana-
tion (data not shown). As another mechanism for the IgG
staining, formation of immune complexes between insulin
and anti-insulin antibodies has been suggested previously
[23,24]. However, their study revealed that glomerular
binding of FITC-labeled insulin was also seen in some
patients who had not received insulin. In our study, there
was a very high prevalence (83%) of IgG staining, while the
prevalence of insulin use at the time of renal biopsy was
much lower (48.5%). Consequently, the main mechanism of
linear IgG staining in DN could be penetration of serum
proteins into the basement membrane secondary to charge
and size selectivity impairment with consequent GBM
thickening.
This study had several limitations. First, it was a retro-
spective cohort study performed at a single center and the
subjects were not stratified by the indication for renal biopsy,
suggesting that there might have been selection bias.
Therefore, it is difficult to apply our results to the clinical
practice in all CKD patients with diabetes. However, given the
results of Sharma et al. that relatively high proportion (over
one third) of patients with diabetes who underwent renal
biopsy had DN alone [25], it may be useful to apply some
important pathological findings such as IgG linear staining to
predicting renal prognosis in those patients. On the other
hand, we investigated a larger sample size than previous
studies, and this was the first investigation into the associa-
tion between the characteristic linear immunofluorescent
staining for IgG in DN and the long-term renal prognosis.
Second, our IgG scoring system might not have sufficient
validity. However, we repeated the scoring of renal biopsies
and assessed inter-observer concordance by using weighted k
statistics, which revealed relatively good agreement. Al-
though we could not strictly quantify the intense of
immunofluorescent staining for IgG, we could show a trend
that more intense linear IgG staining is associated with worse
renal prognosis of DN. Third, in this study, there were
significantly more patients with type 1 diabetes in the group
with IgG score 2 than in the group with IgG score 1 or 2.
However, in our multivariate models, there was no significant
difference of HR for the renal survival between patients with
type 1 diabetes and those with type 2 diabetes (data not
shown). Finally, the treatments provided during follow-up,
including renin-angiotensin inhibitors (ACE-I and ARB),
glycemic control, and blood pressure control, were not
sufficiently examined and adjusted in this study. However,
there were no significant differences with regard to use of
ACE-I or ARB during follow-up among the patients with
different IgG scores. Glycemic control during follow-up also
showed no marked differences between IgG scores, which
was supported by no significant difference of HbA1c during
follow-up or of the final use of erythropoietin-stimulating
agents. With regard to blood pressure control, the average
systolic and diastolic blood pressures during follow-up werelower than those at baseline for each glomerular class, and
the number of antihypertensive agents in use showed an
increase at final follow-up. However, the average systolic
blood pressures during follow-up of patients with a staining
score of 1 or 2 was >140 mmHg and it was significantly higher
for a score of 1 than a score of 0.
In conclusion, more intense linear IgG staining of DN is
associated with higher HRs for renal death. After adjustment
for various clinical factors and other renal pathological
findings, the HRs of higher IgG scores were still higher than
the HRs of lower IgG scores. These results suggest that linear
immunofluorescent staining for IgG may be a useful prognos-
tic finding in patients with DN.
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